In-Depth PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report: Business Trends, Growth Factors, and Forecast to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
The market size for PD-1 and PDL1 inhibitors, also known as immune checkpoint inhibitors, has experienced swift growth in the last few years. The market is projected to expand from $45.8 billion in 2024 to $52.49 billion in 2025 with a compounded annual growth rate (CAGR) of 14.6%. The surge in growth during the historical interval can be linked to advancements in immunotherapy, amplified clinical successes and approvals, rising cancer rates, a shift in the approach to cancer treatment, collaborations, and investments in research.
The market for PD-1 and PDL1 inhibitors, also known as immune checkpoint inhibitors, is poised to experience robust growth in the forthcoming years. It is projected to escalate to a value of $89.62 billion by 2029, growing at a compound annual growth rate (CAGR) of 14.3%. This estimated growth during the forecast period can be credited to the expansion of indications, advancements in biomarker research and personalized healthcare, an increase in clinical trials and research partnerships, as well as improvements in the global healthcare infrastructure. Significant trends projected during this period encompass a prioritization of patient access and affordability, global partnerships for clinical trials, combinations of immunotherapy protocols, a shift towards patient-centric practices, and updates and approvals from the regulatory bodies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10788&type=smp
Which Factor Is Shaping The Future Of The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
Expectations for the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market are high due to the increasing instances of cancer. Cancer happens when certain cells multiply uncontrollably and spread throughout the body. PD-1 and PD-L1 inhibitors are used to combat this disease by enabling the body’s immune system to fight against the cancer cells. As a result, as the number of cancer cases rises, so does the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. For instance, it was reported by the Belgium-based joint research center of the European Commission, the European Union Science Hub, in October 2023 that new cancer cases had increased by 2.3%, amounting to 2.74 million within the two years leading up to 2022. Similarly, there was a 2.4% increase in cancer-related fatalities within the preceding two years. Consequently, the surge in cancer cases worldwide is expected to drive growth in the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market.
What Is The Segment-Wise Breakdown Of The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market?
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market covered in this report is segmented –
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users : Hospitals, Specialty Clinics, Academic and Research Institutions
Subsegments:
1) By Nivolumab: Monotherapy, Combination Therapy
2) By Pembrolizumab: Monotherapy, Combination Therapy
3) By Atezolizumab: Monotherapy, Combination Therapy
4) By Avelumab: Monotherapy, Combination Therapy
5) By Durvalumab: Monotherapy, Combination Therapy
Which Trends Are Redefining The Future Landscape Of The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Industry?
Major firms within the PD-1 and PDL1 inhibitor/immune checkpoint inhibitor sector are turning to strategic investments, such as the move by Regeneron Pharmaceuticals, Inc. to buy out Sanofi’s share of their mutual partnership on Libtayo (cemiplimab). This move granted exclusive global rights to Regeneron for the medication’s research, marketing, and production. The payment plan included a $900 million payment upfront, along with ongoing royalties and future milestone payments. To exemplify, in June 2022, U.S. based Regeneron Pharmaceuticals, Inc. shelled out $900 million to gain exclusive rights to develop, market, and manufacture the Libtayo (cemiplimab) globally. Developed using Regeneron’s exclusive VelocImmune technology, Libtayo is an entirely human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells. Approved by the U.S. Food and Drug Administration (FDA) and various regulatory bodies in over 24 countries, Libtayo is a cemiplimab-rwlc monotherapy treatment for select patients with advanced non-small cell lung cancer (NSCLC), both advanced cutaneous squamous cell carcinoma (CSCC) and advanced basal cell carcinoma (BCC). As a pioneering PD-1 inhibitor, Libtayo is employed in the treatment of approved non-melanoma skin cancers and is regarded as a standard of care. Sanofi S.A., the French pharmaceutical and healthcare firm was a part of the previous agreement.
Which Companies Hold The Largest Market Share In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Sector?
Major companies operating in the PD-1 and PDL1 inhibitors/ immune checkpoint inhibitors market include Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy’s Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
Get The Full Report Here:
How Does Regional Performance Compare Across The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Industry?
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2024. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10788&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
